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Abstract
Eosinophilic esophagitis (EoE) is a chronic immune 
disease, characterized by a dense eosinophilic infiltrate 
in the esophagus, leading to bolus impaction and reflux-
like symptoms. Traditionally considered a pediatric 
disease, the number of adult patients with EoE is 
continuously increasing, with a relatively higher incidence 
in western countries. Dysphagia and food impaction 
represent the main symptoms complained by patients, 
but gastroesophageal reflux-like symptoms may also 
be present. Esophageal biopsies are mandatory for 
the diagnosis of EoE, though clinical manifestations 
and proton pump inhibitors responsiveness must be 
taken into consideration. The higher prevalence of EoE 
in patients suffering from atopic diseases suggests 
a common background with allergy, however both 
the etiology and pathophysiology are not completely 
understood. Elimination diets are considered the first-
line therapy in children, but this approach appears less 
effective in adults patients, who often require steroids; 
despite medical treatments, EoE is complicated in 
some cases by esophageal stricture and stenosis, that 
require additional endoscopic treatments. This review 
summarizes the evidence on EoE pathophysiology and 
illustrates the safety and efficacy of the most recent 
medical and endoscopic treatments. 
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entity is still unclear, however the involvement of both 
genetic and immune factors have been suggested. 
In this review we summarize the evidence on EoE 
pathophysiology and illustrate the safety and efficacy of 
the most recent medical and endoscopic treatments.
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INTRODUCTION
The eosinophilic esophagitis (EoE) is a chronic immune 
disease, characterized by a dense eosinophilic infiltrate 
into the esophagus. Dysphagia and food impaction 
episodes are recognized as the main symptoms of 
EoE in adults, however regurgitation, chest pain and 
heartburn may also be referred[1].
Considered as a pediatric disease until few years 
ago, it is now clear that EoE may also occur in adults, 
especially young Caucasian man[2]. A rapid increase 
of incidence in the last decades has been registered, 
however a retrospective study[3] on biopsies collected 
between 1982 and 1999 revealed that the incidence of 
EoE appears stable, suggesting that the higher rate of 
new diagnosis depends, almost in part, on the improved 
disease recognition. African, West Asian and South 
American population share a low prevalence rate, but 
the real incidence of EoE in these countries remains 
unclear[4,5]. 
The EoE-symptoms pattern is heterogeneous and 
although dysphagia and food impaction are frequently 
reported, patients may also complain of typical and 
atypical gastroesophageal reflux disease (GERD) symp­
toms, leading to a delay in the diagnosis.
Endoscopic features, such as esophageal rings, 
white exudates or plaques, longitudinal furrows, diffuse 
esophageal narrowing, and mucosal fragility, may help 
the diagnosis, but histological identification of predo-
minant eosinophilic-inflammation, with more than 15 
eosinophils for high power field, represents the main 
diagnostic criterion for EoE (Figure 1 and Table 1). 
Nevertheless, the histological evidence of esophageal 
eosinophilia in a subset of proton pump inhibitors (PPI) 
responder patients further complicates the diagnosis. 
Previously considered a GERD­subtype, actually, PPI­
responsive esophageal eosinophilia (PPI­REE) is con­
sidered a different entity, not distinguishable from 
EoE[1,6]; in the Figure 2 it is summarized the diagnostic 
algorithm in case of suspected EoE. 
The pathogenesis of EoE is unknown, but it is 
supposed to be multifactorial with genetic, immunologic 
and environmental factors being all involved. There 
is evidence that EoE is more prevalent in patients 
suffering from food-allergy, rhinitis, asthma or atopic 
dermatitis[7,8]. Interestingly, all these pathologies share 
an altered immune response to common antigens, which 
determinates an aberrant Th2-response, and, hence, 
the uncontrolled activation of eosinophils, mast cells and 
basophils[9-13]. 
Specific allergy testing, or empiric elimination diets 
represent the first line therapy in children with EoE[1,14]. 
Topical corticosteroids are considered the mainstay of 
therapy for adult patients[1,15], while systemic steroids 
are reserved to patients with persistent eosinophilia[1]. 
Besides its central role in the diagnosis of EoE, endo-
scopy has also of great impact on the treatment of EoE 
fibrotic complications[1,16]. 
This review summarizes the most recent evidence on 
the pathogenesis of EoE, focusing on the role of genetic 
and immunologic factors and illustrates the safety and 
efficacy of the most recent medical and endoscopic 
treatments. 
PATHOPHYSIOLOGY
Genetic factors
The higher risk of EoE in familiars of affected patients 
supports the hypothesis of genetic predisposition. The 
latest familial study[17] estimated that 2.4% of proband 
siblings’ also had EoE, with a 40-folds higher risk, than 
general population. 
The incidence of EoE is higher in monozygotic twins 
(41%), but the observation that the disease also occurs 
in 21% of dizygotic twins suggests a role for environ-
mental factors, especially in the early-life[17]; by using a 
complex statistical model it has been estimated that the 
contribution to the familiar risk depends by hereditability 
and exposure to common environment for 14.5% and 
80%, respectively[17]. 
Three different approaches have been used to 
identify the genes involved in EoE predisposition: The 
association with Mendelian syndromes, the search 
for a specific gene and the genome-wide association 
studies[18] (Table 2). 
An increased prevalence of EoE has been reported 
in patients affected by hypermobile connective tissue 
diseases, like Marfan, Ehler-Danlos and Loeys-Dietz 
Syndromes; interestingly, these pathologies are cha-
racterized by a defective transforming growth factor 
(TGF)­β pathway, and the observation that this factor is 
increased in the esophagus of both syndromic and not 
EoE likely supports its causative role[19-21]. A major risk 
of EoE has been also described in some pro-allergenic 
Mendelian diseases, like the “Iper-IgE syndrome”[18] and
an autosomal dominant disease belong to Mast-cell 
Activation syndromes, characterized by high levels of 
mast cell tryptase, this association strongly suggests the 
pathogenic association between EoE and atopic disea-
ses[22]. This concept is further supported by the association 
between EoE and a rare syndrome characterized by 
severe atopic dermatitis, multiple allergies and metabolic 
syndrome (SAM); this syndrome is characterized by a 
mutation of desmoglein-1 gene’s[18,23], whose expression 
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is significantly reduced in idiopathic EoE[24].
Candidate-gene identification studies allowed iden-
tifying the putative factors associated with EoE in 
non-Mendelian syndromes. A single-nucleotide poly-
morphism (SNP) in the gene CCL26, encoding for the 
eotaxin­3, was associated with EoE[25]. This protein is 
overexpressed in esophageal epithelial cells of affected 
patients, and plays an important role in the chemotaxis 
of eosinophils[26,27]. Similarly, a SNP in the gene encoding 
for the filagrin, a structural membrane protein involved 
in epithelial cells­extracellular matrix interaction has 
also been identified[18]. Several genes were found to 
be associated with EoE by genoma wide association 
studies. In one of the most recent report[28] a significant 
association between a locus on 5q22, encoding for the 
cytokine thymic stromal limphopoietin (TSLP) and EoE 
was reported. Although the specific mechanism remains, 
yet, to be clarified, TSLP has been demonstrated to have 
a pivotal role in the activation of basophils in human and 
animal models of EoE[29,30]. In the same study[28] also 
the CAPN14 gene, encoding for the calpain subfamily of 
proteolytic systems, was identified; more precisely this 
protein, that is specifically expressed by epithelial cells 
of the esophagus, is activated by interleukin (IL)-13 and 
participates to inflammatory process[28]. 
Immune system factors
The EoE is characterized by a prevalent eosinophilic 
infiltrate in the lamina propria and submucosa of the 
esophagus. The precise mechanisms of such localized 
inflammatory reactions are not recognized yet, but it 
is suggested that different cytokines are involved in 
the maturation and migration of eosinophils. In particu-
lar, IL-5, IL-13 and granulocyte-macrophage colony-
stimulating factor are produced by different cell types, 
included esophageal epithelial cells, after an appropriate 
stimulation by the antigen-presenting cells (APCs)[31]. 
As shown in Figure 3, the evidence that in EoE patients 
there is desmoglein-1-dependent altered barrier 
function[23] have led some authors to hypothesize that 
the increased permeability of esophageal epithelium 
could facilitate the passage of different antigens, that 
causes the activation of APCs and invariant natural killer 
T-cells. These cells, if properly stimulated, are able to 
prime a Th2 immune response, by the production of 
IL-13 and IL-4[32]. However, whether the barrier impair-
ment represents a primum movens, or an epipheno-
menon in the context of the eosinophilic­inflammation 
remains unclear. Sherrill et al[33] have demonstrated that 
esophageal epithelial cells express toll­like receptors, 
whose antigens-mediated activation, through the 
production of IL-5 and IL-13[34], is able to trigger a Th2-
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Figure 1  Endoscopic and microscopic findings in eosinophilic esophagitis. A: Esophageal rings; B: White exudates, longitudinal furrows and mucosal fragility; 
C and D: Esophageal mucosa infiltrated by several eosinophils (red cells) (C: Original magnification HE 150 ×; D: HE 400 ×).
Table 1  Endoscopic and histological features of eosinophilic 
esophagitis
Endoscopic features
   Esophageal rings
   White exudates or plaques
   Longitudinal furrows
   Diffuse esophageal narrowing
   Mucosal fragility
Histological features
   Eosinophilic infiltration (≥ 15 eos/hpf)
   Eosinophilic degranulation
   Basal zone hyperplasia
   Eosinophilic micro-abscesses
   Spongiosis or dilated intercellular spaces
   Intramucosal lymphocytes 
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basophils[31].
The increased release of these cytokines in both 
the esophagus and the blood of EoE patients has been 
demonstrated in different studies[35,36], and, although 
need to be further clarified, their role in the pathogenesis 
of EoE appears to be fundamental. 
IL-4 and IL-13 are able to prolong the T-cell survival 
and to increase eosinophilic migration through the 
release of Eotaxin­3 and TSLP by epithelial cells[37]; 
recently, Zhu et al[38] found that IL-15 is also enhanced 
in EoE and, most interestingly, they demonstrated that 
IL-15 receptor deficient mice are protected from EoE, 
but not from other allergic diseases, supporting a specific 
role of IL-15 in the “allergic-pathway” of esophagus. 
Although the eosinophilic infiltration represents the main 
characteristic, it is of relevance that other immune cells, 
like basophils and mast cells, are also involved in the 
response with the production of other cytokines and 
the proliferation of eosinophils, T-cells, mast cells and 
Absence of eosinophilic inflammation Eosinophilic inflammation
PPI bid for 4 wk
Persistent eosinophiliaHistological remission
PPI-responsive esophageal eosinophilia Eosinophilic esophagitis
Specific diet or steroidsPPI-therapy 
Proximal and distal esophageal biopsies
EGD
Dysphagia - food impaction - atypical GERD symptoms
Endoscopic EoE-features or no lesionsMacroscopic evidence of specific disease
Specific treatment
Figure 2  Diagnostic flow-chart of eosinophilic esophagitis. GERD: Gastroesophageal reflux disease; EoE: Eosinophilic esophagitis; PPI: Proton pump inhibitors; 
EGD: Esophagogastroduodenoscopy.
Table 2  Genetic factors involved in eosinophilic esophagitis
Genes Encoded protein Mechanism of action Ref.
Mendelian syndromes
   FBN1 (Marfan syndrome) Fibrillin Alteration of TGF-β pathway [19]
   COL (Elher-Danlos syndrome) Collagen Alteration of TGF-β pathway [19]
   TGFBR (Loeys-Dietz syndrome) TGF-β-promoters Alteration of TGF-β pathway [21]
   STAT3 (Iper-IgE syndrome) Transcription activator 3 Aberrant cytokines production [18]
   DSG1 (SAM) Desmoglein1 Loss of cell-cell adhesion [23]
EoE-associated genetic variants
   CCL26 Eotaxin-3 Eosinophilic chemo-attraction [25]
   FLG Filaggrin Epithelium-ECM interaction [18]
   TSLP (5q22) TSLP Basophils chemo-attraction [28,29]
   CAPN14 Calpain 14 Proteolytic effects [28]
TGF: Transforming growth factor; ECM: Extracellular matrix; SAM: Severe atopic dermatitis, multiple allergies 
and metabolic syndrome.
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    IL-5
Figure 3  Pathophysiological mechanism involved in eosinophilic infiltration 
of esophageal mucosa. IL: Interleukin; APC: Antigen-presenting cell.
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pathogenesis of EoE and they likely contribute to the 
amplification of the esophageal inflammatory response 
and mucosal damage[18,20,29].
Mechanisms of mucosal damage and fibrosis
Food impaction and dysphagia are the main symptoms 
in patients with EoE and these are a direct consequence 
of the esophageal mucosa remodeling and fibrosis. 
Eosinophils synthetize and release many proteins 
and mediators, in particular major basic protein (MBP), 
eosinophil cationic protein, eosinophil peroxidase, 
eosinophil­derived neurotoxin, TGF­β, IL-13 and platelet-
activating factor. Although all these mediators play a 
key role in the tissue damage and remodeling, the most 
robust data are about MBP and TGF­β[37].
MBP is able to directly damage epithelial cells, but 
also to induce mast cells degranulation, increasing the 
release of proteolytic enzymes, tryptase and chymase, 
that further participate to the deconstruction of the 
extracellular matrix[39]; MBP is also able to stimulate 
the production of fibroblast growth factor­9, leading to 
fibroblasts proliferation and activation[40]. Similarly, TGF­β 
induces both fibroblasts activation and contraction, 
causing their transformation into myo­fibroblasts[41]; in 
addition at high concentration TGF­β stimulates epithelial 
cells to assume phenotypical characteristic of fibroblasts, 
a process named epithelial-mesenchymal transition[42]. 
These mechanisms act synergistically, determining the 
altered synthesis of extracellular matrix proteins, such 
as collagen, tenascin-C and metalloproteinases[43]. In 
recent studies the periostin, that is highly expressed in 
the esophagus of EoE patients, has been proposed as 
a major determinant of extracellular matrix alteration 
and epithelial barrier function impairment, because of 
its ability to determine collagen cross-linking and to bind 
several matrix proteins and integrins[44].
As mentioned above, other immune cells rather than 
eosinophils participate to the inflammatory response 
described in the EoE; recently, the ability of epithelial and 
mesenchymal cells to synthetize and release different 
molecules has been also suggested to contribute to 
tissue damage[12,20,45]. In addition, some authors found 
a correlation between the inflammatory cells infiltrate 
and enteric neurons alterations, but the role of enteric 
nervous system impairment in the process of mucosal 
damage has not been clarified, yet[46].
THERAPEUTIC OPTIONS 
The “3 D-approach” summarizes the three major treat-
ments for EoE: Diet, drugs and dilation. Although clinical 
remission represents a good parameter to evaluate the 
effectiveness of therapy, the endoscopic and histological 
response is required. The main endpoint of diet and 
drug therapies is the resolution of both symptoms and 
inflammation, however the complete remission is rare, 
and the relief of esophageal symptoms in association 
with a significant reduction of mucosal eosinophilia should 
be considered a good response[1].
Dietary therapy
Specific dietary approaches are considered the first­line 
therapy in the treatment of EoE in children, due to the 
lack of adverse effects and the high rate of response. 
Three different dietary patterns may be used: (1) ele-
mental diet; (2) allergy test-based diet; and (3) empiric 
elimination diet[47].
The elemental diet demonstrates the high rate of 
response (almost 90% in children, 70% in adults), with 
a rapid relief of symptoms associated with histological 
remission. This diet contemplates the use of amino-
acid based liquid formulas for 4-6 wk, followed by the 
histological evaluation of response. If the remission is 
achieved, foods are slowly reintroduced, following a 
strict scheme which contemplates four different food 
groups, based on their allergenic potential. A single 
food of each group should be reintroduced every 5-7 d; 
in absence of symptoms’ recurrence, the endoscopic 
and histological evaluation should be performed before 
starting the reintroduction of foods from another group. 
If a specific food determinates esophageal symptoms, 
it should be excluded and the next food of the same 
group tested. Despite the high rate of response, this 
diet is rarely accepted by patients[48,49].
The allergic-test driven diets showed a rate of 
response of 70% in children, using the combination of 
both skin prick and patch tests to identify trigger-foods; 
this dietary pattern allows the elimination of specific 
foods, enhancing the compliance, however atopy patch 
test are not universally accepted for food allergy[50,51]. 
Moreover, given that the rate of response to this diet in 
adults is lower, this approach is not recommended in 
this patients.
The empiric diets, instead, are based on the exclu­
sion of the most allergenic foods, such as cow’s milk 
protein, soy, wheat, egg, peanut/tree nut, and fish/
shellfish, independently on allergic tests. This dietary 
therapy has shown a rate of response of almost 70% 
in both children and adults. However, if the remission 
is achieved, an endoscopic and histological evaluation 
should be performed after the reintroduction of each 
food[52,53]. 
In conclusion, although the exclusion of trigger­
foods allows a long-term remission without drugs, the 
high cost of such diets, especially aminoacid based-
formulas, the poor compliance and the need for multiple 
endoscopies, represent important disadvantages for 
dietary therapy.
Corticosteroids
Several studies have demonstrated the efficacy of 
systemic corticosteroids, such as prednisolone or methyl-
prednisolone, in the remission of both symptoms and 
eosinophilic infiltration, however the recurrence after 
the tapering is usually observed. Long-term therapy 
with corticosteroids is limited by the important adverse 
effects, hence systemic steroids may be used to rapidly 
induce remission, but a different maintenance therapy 
has to be set[54]. Topical steroids, in particular fluticasone 
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and budesonide, have shown a good rate of response, 
reducing adverse effects also during long-term treat-
ment[55,56]. Due to the lack of specific dispenser, multi­
dose inhalers should be used, and patients have to be 
instructed to swallow, rather than inhale, the product[57]. 
A viscous compound of budesonide and sucralose, 
has also been tested, obtaining excellent results[58]. 
Topical steroids have shown a good safety profile, and 
are actually considered the first-line therapy, after the 
PPI trial, in EoE patients. However, some cases of eso-
phageal candidiasis and herpes infections have been 
described[59,60]. 
PPI 
When the first consensus guidelines for EoE was 
published in 2007, a physiological 24h-pH-metry and 
the persistence of symptoms despite PPI therapy were 
considered major criteria for diagnosis of EoE. In the 
last years, several studies have shown that almost 40% 
of patients with clinical, endoscopic and histological 
features of EoE responds to PPI therapy, independently 
on the results of 24 h-pH-metry[61,62]. 
These data questioned the relationship between 
GERD and EoE, introducing a novel entity, named PPI­
REE, in the consensus of 2011[63]. Actually considered 
more a subtype of EoE, rather than atypical GERD, this 
pathology is defined by the presence of all hallmarks 
(clinical, endoscopic and histological) of EoE, associated 
with a complete (clinical, endoscopic and histological) 
remission during PPI therapy[1]. Considering that different 
studies have demonstrated that patients with PPI­REE 
share the same genetic and phenotypic background of 
EoE­subjects, nowadays PPI bid is considered the first­
line therapy in all patients with EoE features[1,64].
PPI­REE opened a new field of research, focused 
on the role of reflux in the pathogenesis of esophageal 
eosinophilia[65]. The hypothesis that gastroesophageal 
reflux, even if not pathologic, could enhance epithelial 
barrier dysfunction, allowing the passage of multiple 
antigens through the mucosa, has been proposed and 
evaluated. Different studies have demonstrated that 
gastric reflux is able to enlarge intracellular space, and 
the increased transit of molecules through esophageal 
epithelium has also been observed in both GERD and 
EoE[66,67]. Accordingly, the exposition of several antigens 
to APC may induce, in predisposed subjects, a cascade 
of events, triggering a Th2-response, and, consequently, 
the eosinophilic infiltration. In this case the therapeutic 
effects of PPIs, will depend on their ability to favorite the 
regeneration of epithelial barrier, reducing the antigen 
exposition and, hence, the amplification of immune 
response.
According to others, also GERD, as EoE, represents 
an immune­mediated pathology, in which acid reflux 
stimulates the release of cytokines, inducing a specific 
Th1-response. Therefore, the activation of immune system 
and the production of toxic mediators determinates 
mucosal erosions, rather than the direct caustic action of 
acid[68]. These authors suggest that in “atopic-subjects”, 
the typical response to acid reflux switch to a Th2-
response, causing an EoE-like damage of the esophagus. 
Therefore, the reduction of immunogenic trigger, by the 
inhibition of acid secretion, will determinate the resolution 
of damage. Furthermore, a direct anti-inflammatory 
effect of PPIs has been recently demonstrated. In 
particular, different studies have pointed out the reduction 
of eotaxin 3 and Th2-mediators, after treatment with 
PPI in the mucosa of patients with diagnosis of both EoE 
and PPI­REE. These events have been observed both in 
vitro and in vivo experiments, suggesting that PPIs anti­
inflammatory action is acid­independent[69-71]. 
Summarizing, at the baseline, is not possible to 
discriminate between EoE and PPI­REE, and, although 
the probability of PPI response in patients with pathologic 
24 h-pH-metria is higher, PPIs trial still represents the 
only instrument to differentiate these entities (Figure 
2)[72,73]. 
Other pharmacological treatments
Given the association with other atopic diseases, 
leukotriene antagonist and mast cells stabilizers, such 
as montelukast and cromolym, have been tested in the 
treatment of EoE, however all studies showed a poor 
efficacy of these drugs in both symptomatic and histolo­
gical remission[74].
Specific antibodies against IL-5 and IgE were also 
tested, especially for treating steroid-refractory patients. 
However, despite the initial promising results, the 
controlled clinical trials have shown a similar response 
in treated and placebo subgroups[75-78]. Interestingly, 
a recent trial testing a human antibody against IL-13 
showed a significant improvement of symptoms and 
eosinophilic infiltration, however the primary endpoint, 
the reduction of 75% of esophageal eosinophils, have 
been not achieved[79]. 
The failure of such specific therapy likely depends on 
the redundancy, in fact multiple cytokines share similar 
effects, allowing the persistence of inflammation after 
the blockage of single molecules. 
Endoscopic treatment
Due to the fibro-stenotic evolution, strictures are 
frequently found in patients affected by EoE, hence 
endoscopic dilation have a key role in the treatment of 
this entity[1]. Several studies have shown the efficacy 
and safety of esophageal dilation, independently on the 
chosen technique. Wire-guided bougies, through-the-
scope balloons, and non-wire-guided bougies have been 
indistinctly used[80,81]. Nowadays, there are not available 
data on the best endoscopic technique, because 
comparing studies are lacking.
Due to the long-term efficacy of this procedure in 
the treatment of EoE-related dysphagia, some authors 
have proposed dilation as initial therapy, however a 
recent study have demonstrated that fluticasone inhaler, 
followed by dilation if necessary, is the most economical 
initial strategy. Moreover, although dilation rapidly 
improve symptoms, this procedure did not influenced 
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esophageal inflammation, hence further therapies should 
be set after the treatment[82].
CONCLUSION
EoE represents a multifactorial disease, in which both 
genetic predisposition and environmental factors con-
tribute to disease manifestations. Although in the 
last years many studies have been performed, its 
pathophysiology remains unclear, likely reflecting the 
heterogeneity of disease phenotype. 
The EoE-symptoms pattern is heterogeneous, 
dysphagia and food impaction are frequently referred, 
however also atypical GERD symptoms may be reported. 
The histological identification of a prevalent eosinophilic 
esophageal infiltrate represents the major diagnostic 
criterion for EoE, however only the PPI-trial allows to 
distingue EoE from PPI­REE. 
The good response to diet therapy in children, 
supports the role of food as a major trigger factor, 
leading to define EoE a subtype of food­allergy. For this 
reason, elimination diets and corticosteroids represent 
the mainstay of EoE-therapy, while endoscopic dilation 
have a key role in the treatment of fibrotic complication. 
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